Research Analysts’ Recent Ratings Changes for BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals (NASDAQ: BCRX) recently received a number of ratings updates from brokerages and research firms:

• 5/9/2026 – BioCryst Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “hold”.
• 5/7/2026 – BioCryst Pharmaceuticals had its price target raised by Citizens Jmp from $25.00 to $28.00. They now have a “market outperform” rating on the stock.
• 5/7/2026 – BioCryst Pharmaceuticals had its price target lowered by Wedbush from $22.00 to $21.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – BioCryst Pharmaceuticals had its price target lowered by Needham & Company LLC from $18.00 to $16.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the transaction, the insider owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is owned by corporate insiders.

Get BioCryst Pharmaceuticals Inc alerts:

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Further Reading

• Five stocks we like better than BioCryst Pharmaceuticals
• Why Trump’s Amazon Stock Sale May Not Matter at All
• Why Applied Optoelectronics Stock May Be Near a Turning Point
• From High-Yield to High-Growth: 3 Stocks Boosting Dividends
• Is Everspin Technologies the Next AI Edge Breakout?

Receive News & Ratings for BioCryst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.